Laurus Labs independent director tenure concludes on July 6, 2026

0 min read     Updated on 07 Jul 2026, 02:26 AM
scanx
Reviewed by
Suketu GScanX News Team
AI Summary

Mrs. Aruna Bhinge's tenure as Independent Director at Laurus Labs concluded on July 6, 2026, following the completion of her second term. The company had previously intimated the exchanges on April 30, 2026, regarding the necessary details under the SEBI Master Circular.

powered bylight_fuzz_icon
44903693

*this image is generated using AI for illustrative purposes only.

The tenure of Mrs. Aruna Bhinge as an Independent Director of laurus labs concluded on July 6, 2026, following the completion of her second term with the pharmaceutical company. The departure took effect at the close of business hours on the specified date, as confirmed in a regulatory filing addressed to the stock exchanges.

Laurus Labs had initially informed the exchanges about the impending conclusion of her tenure through an intimation dated April 30, 2026. The company confirmed that all necessary details required under SEBI Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 were submitted in the prior communication.

The filing was submitted by G. Venkateswar Reddy, the Company Secretary & Compliance Officer of Laurus Labs Limited. The document was digitally signed on July 6, 2026, at 19:44:22 IST.

Key Details

Detail Information
Director Name Mrs. Aruna Bhinge
DIN 07474950
Role Independent Director
Tenure Conclusion July 6, 2026
Reason Completion of second term

Historical Stock Returns for Laurus Labs

1 Day5 Days1 Month6 Months1 Year5 Years
-0.56%-3.18%+4.59%+30.19%+89.27%+114.98%

Who will Laurus Labs appoint to replace Mrs. Aruna Bhinge, and how might this impact the board's expertise?

Will the departure of an Independent Director influence Laurus Labs' strategic decisions in the near term?

How will the market react to this leadership change, and could it affect investor confidence?

Laurus Labs appoints Independent Directors for five years

1 min read     Updated on 03 Jul 2026, 04:59 PM
scanx
Reviewed by
Naman SScanX News Team
AI Summary

Laurus Labs Limited appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for a term of five years effective July 2, 2026, during its 21st Annual General Meeting. The meeting ratified the adoption of audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and approved two interim dividends totaling ₹2 per share for FY26. Shareholders also re-appointed Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava as Directors and approved remuneration for Non-Executive Directors and Cost Auditors.

powered bylight_fuzz_icon
44559776

*this image is generated using AI for illustrative purposes only.

Laurus Labs Limited appointed Dr. Shekhar Chintamani Mande and Ms. Sutapa Banerjee as Independent Directors for a term of five years effective July 2, 2026. The 21st Annual General Meeting (AGM), held via video conferencing, also ratified the adoption of audited financial statements for the financial year ended March 31, 2026, and approved two interim dividends totaling ₹2 per share for FY26.

The meeting ratified the first interim dividend of ₹0.80 per share and the second interim dividend of ₹1.20 per share, both paid for the financial year 2025-26. Shareholders approved the payment of remuneration to Non-Executive Directors, including Independent Directors, and the remuneration payable to Cost Auditors for the financial year ending 2026-27. Mr. Krishna Chaitanya Chava and Mrs. Soumya Chava were re-appointed as Directors, having retired by rotation.

Dr. Shekhar Chintamani Mande (DIN: 10083454) and Ms. Sutapa Banerjee (DIN: 02844650) are not related to any of the Directors or Key Managerial Personnel of the company. Based on their declarations, they are not debarred from holding the office of Director by virtue of any SEBI order or any other such authority. The appointment of Ms. Banerjee received 91.65% votes in favour.

The remote e-voting facility, provided by National Securities Depository Limited (NSDL), was open from June 29, 2026, to July 1, 2026. A total of 1,189 members participated in the e-voting process. The meeting commenced at 3:00 p.m. IST and concluded at 3:57 p.m. IST. Mr. Y. Ravi Prasada Reddy, Proprietor of M/s RPR & Associates, served as the Scrutinizer for the voting process.

Resolution Type Votes For (%) Votes Against (%)
Adoption of Financial Statements Ordinary 99.75 0.25
1st Interim Dividend (₹0.80/share) Ordinary 99.99 0.00
2nd Interim Dividend (₹1.20/share) Ordinary 99.99 0.00
Re-appointment of Mr. Krishna Chaitanya Chava Ordinary 99.28 0.71
Re-appointment of Mrs. Soumya Chava Ordinary 99.28 0.71
Appointment of Dr. Shekhar Chintamani Mande Special 99.99 0.00
Appointment of Ms. Sutapa Banerjee Special 91.65 8.34
Remuneration to Non-Executive Directors Ordinary 88.85 11.14
Remuneration to Cost Auditors Ordinary 99.99 0.00

Historical Stock Returns for Laurus Labs

1 Day5 Days1 Month6 Months1 Year5 Years
-0.56%-3.18%+4.59%+30.19%+89.27%+114.98%

How will the expertise of the newly appointed Independent Directors influence Laurus Labs' strategic direction over the next five years?

What is the company's capital allocation strategy regarding dividends given the approval of two interim dividends for FY26?

Will the significant dissent on remuneration for Non-Executive Directors lead to a review of the company's executive compensation policies?

More News on Laurus Labs

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+89.27%